{"name":"Adaptive Biotechnologies","slug":"adaptive","ticker":"ADPT","exchange":"NASDAQ","domain":"adaptivebiotech.com","description":"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.","hq":"Seattle, WA","founded":0,"employees":"624","ceo":"Chad Robins","sector":"Diagnostics / Immune Medicine","stockPrice":13.15,"stockChange":0.02,"stockChangePercent":0.15,"marketCap":"$2.1B","metrics":{"revenue":295407008,"revenueGrowth":35.1,"grossMargin":43.7,"rdSpend":93769000,"netIncome":-59499000,"cash":218334000,"dividendYield":0,"peRatio":-50.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Adaptive Biotechnologies reported its fourth quarter and full year 2023 financial results, with revenue of $123.4 million and a net loss of $73.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Adaptive Biotechnologies Announces Collaboration with Merck to Develop Immuno-Oncology Therapies","summary":"Adaptive Biotechnologies announced a collaboration with Merck to develop immuno-oncology therapies using its immune medicine platform.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"FDA Grants Breakthrough Therapy Designation to Adaptive Biotechnologies' Tumor-Infiltrating Lymphocyte (TIL) Therapy","summary":"The FDA granted breakthrough therapy designation to Adaptive Biotechnologies' TIL therapy for the treatment of certain types of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"earnings","source":"simplywall.st","summary":"Adaptive Biotechnologies (ADPT) Is Up 15.3% After Beating Q4 Views And Striking Pfizer Deals - simplywall.st","headline":"Adaptive Biotechnologies (ADPT) Is Up 15.3% After Beating Q4 Views And Striking Pfizer Deals","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOanlsN0ZsVUNTaDEyZVZqUkJua2w2eFA4T3hybnBWV1NqNWJPVkxfWHFmR0tmLXplSm1aRnF0bXd3eDZ4eVItVEtEMU83WVhqdVoxR2lYTTBOb0lWdThUenBHeWhqWUlCd0U3MlVTUENkSU9tb0E0c01ib2Z5UENFMHM1WkU5ekJsd29xRWt0XzhGVWNyWUhCMlp2NTV3cEtxVW1CUWxYZ0xDYU5zb043dFFhQQ?oc=5","date":"2026-04-05","type":"earnings","source":"Yahoo Finance","summary":"A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer Agreements - Yahoo Finance","headline":"A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer Agreements","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"pipeline","source":"simplywall.st","summary":"A Look At Adaptive Biotechnologies (ADPT) Valuation After Strong 1 Year Share Price Performance - simplywall.st","headline":"A Look At Adaptive Biotechnologies (ADPT) Valuation After Strong 1 Year Share Price Performance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPcmdwR1JfNGllVXFVS29uTmc3VVY3LXBjUWRVc1VEMHVGY2piOXRyLTFSTlFHWTJDc3dNMEVXWUEwOVg3S0JTcUhsQ00xTlYxVzZKeGpaemhQOUpsRlBWREYxUm1pNUwxeEZDOUFqdVdWOXJ6QzFNb2VmUVBpdEFLdDI2QlRiemZaWWRPUmZSRmZhdENkQWE0VW1JWm5jN0Q3OWJmQWxnY0xFRlk5clFyN1lTc2liWmUwTDdXU1ptWEF1dGpaMmR4YV9FU2dDWl9fUnVkMDFnR09qanBneGQyS3FOeG5HSkhLU3U2QW1YUdIB9AFBVV95cUxPdXk2bk5YQXM1bXN4U3cxdGlibDRXLV9hR0dsbXkzNmJiaVRBQzFYSmxGdVlTUDYyeHVLc3dxYm9ueU9GY1Q4R3k4TThLUHhOc0QwX0VyWHpwc2htMUdaOUx3QmFEX1I0ekxzNnRqckxQNmFkbUhSaUdiUTlSZnRZMmVrWlQ0MDZEN0dyX0xCUlFlaHdkUkRJY3M4U2VvUmNWRXAxS1hCSGZsa25oLTFRVDE1RHZ6ajNDQXdfLVotOXh4VHdzZlpZa19FMVhNbnR5cW14ZmdtNHBqZkRCc0d3b3RwdERCMV9ObF9nRFl1ZnJxVVF3?oc=5","date":"2026-04-02","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess Adaptive Biotechnologies (ADPT) After Its Volatile Share Price Run - simplywall.st","headline":"Is It Time To Reassess Adaptive Biotechnologies (ADPT) After Its Volatile Share Price Run","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNcUxpbTBSNGstLV9ua2U2bGY1eU1ZT3lqeGNvdVBRbGVnemRYOWJRdzFDekVoTHVfSjdkMFJfNWZMdDNMbFVqczNGUGZSWTZKUE4tQkw4ZzFpSWpOd05nbDgzeS1YQmZIdXA5bkkxSTNQS09Ydk82VEU1aVAyUU5iT3M3cVNvSkpTRGNqVzRQbmlvMGJKVy03SVZoSXkxa3lXM2dPOWhKWGI5bkRycHgwVThmUm5tM2wzcFIwUTl6V0dUMnVNWUJDdk1RbnE1YmRi?oc=5","date":"2026-03-29","type":"pipeline","source":"Sahm","summary":"A Look At Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness - Sahm","headline":"A Look At Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-16","type":"earnings","source":"simplywall.st","summary":"Adaptive Biotechnologies (ADPT) Is Down 11.9% After MRD-Led Earnings Beat And Tax-Driven Insider Sales - Has The Bull Case Changed? - simplywall.st","headline":"Adaptive Biotechnologies (ADPT) Is Down 11.9% After MRD-Led Earnings Beat And Tax-Driven Insider Sales - Has The Bull Ca","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOQ3lDUDJuakxhVGJIR0xlRlRncC1lV2p6aVF6ci14ZTNYbC10WXpOazM0ODBmNTVOTTgtUTlkOWxxcFpYWlI1cEtGbF91ZVNYSmdTVEVBN3pfUkV0bnNySlFGeDlkY25wTVJ0YlZDSWstcjBtU195T1RiS25lVmdzYWM0eWJJMXpEY0RjX3IxeThLV193M1RWZHZR?oc=5","date":"2026-02-28","type":"pipeline","source":"Finviz","summary":"Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)? - Finviz","headline":"Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNQXhwYlFyeU1mWjZSM09ORlIydDMyQ3FfMHM5Nm80a2hnUGJ4Y1U4clpzWkdyTU9pczh0N3FEWlNuS01rN0VBVGtuYkFrT2lDQjdDN21BZGF2QnRpWjVaZ01VanAwX094Szc1R2twQW9pa3RYNFdmLU5UQ1g1MndtaUdlT0dlM3Rqek5YRWt3djM?oc=5","date":"2026-02-21","type":"pipeline","source":"Yahoo Finance","summary":"TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT) - Yahoo Finance","headline":"TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPblpJTi0tVXZ6aENJTEpDUVdxRUQ3TkpKTzNLalNiM2pCakJ5djBmSjZXOS15b2NkWXNiN0xrWV9QUm9HVEJRcU9jTEd6QWRGNEVNd2VNWWxScTNpVXktcDhoSzIyOTBDMnFKSGJJRjlxTEJlT3FMX21Mb015WFo5T21LS3hsQXlMZUUzWEs1bktIYmROWnZVZjA2N2tUelViVjd0QzJvS2R1cHptNnBTY1lSX29nS05lb25nMnZn?oc=5","date":"2026-02-05","type":"earnings","source":"Stock Titan","summary":"Biotech Adaptive Biotechnologies lifts 2025 revenue 55%, narrows loss - Stock Titan","headline":"Biotech Adaptive Biotechnologies lifts 2025 revenue 55%, narrows loss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNbkYxYlpDQXdvWGxFU3hlSmFPNlVELUNxaFcxOUh5UkRfWUxWZnNRSU9uRlNyeExxa3ZKbjFwZjdKYU05YU1FbjQ4enMxUDVoOTB3VlVBczRjUTZhRzJsNlc1alRIUFRqUHVPbHJYTEpUdE8wQV9UTndiaHNBdm1QWjFYNm56NmtwcUR6OXptcHhFSjRieDQxNkliSzI4MFFJaVI1ZmEtX3AtUWlleWxkWkVtTkpuMXo0THJyR2xOdXJoYlpiQXZyT2ZpSktCdm1wcUZRYnN0VVVQeGlHTmZUOQ?oc=5","date":"2025-12-15","type":"deal","source":"reuters.com","summary":"Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - reuters.com","headline":"Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOTEdMM0NkYUtCRHBQVXJsbXMyWlJsSXRKVEstQ0EwOW5vS0NuaHh5YjlBLXoxYmwyczFKOEJGY3lmNVRPYlB0bWVFZ21ydFlyWFc4V2pwQng0WUJlREFhSm1EdmJBQzNOY000YXQ1bFFjXzlEY1VZdEhvalFBM3VvNEdjcVFMRXlQN0Z6eXVnS1c?oc=5","date":"2025-12-06","type":"pipeline","source":"StocksToTrade","summary":"Adaptive Biotechnologies’ Stock Faces Turmoil Amid Insider Selling - StocksToTrade","headline":"Adaptive Biotechnologies’ Stock Faces Turmoil Amid Insider Selling","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxObGt4RE5GZEZMV3ZOMmlqY29Ub3hrSm9lR3piR2NSTUZQNC1qTjdqNmRGSk1rd2s5bFFCMUlpeGJsQmhIanhseExKQXBhYm1lS0thTkJ5MDQyYmFuYk05R1RIaTQwRTdtWjU0NS1yT2lPVmhRWEhKS3lBV280SUhmaGVXekFtRE9TblE?oc=5","date":"2025-11-22","type":"pipeline","source":"Yahoo Finance","summary":"Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here’s Why - Yahoo Finance","headline":"Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here’s Why","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Immuno-Oncology","Immune Medicine Diagnostics"],"financials":{"source":"sec_edgar+yahoo","revenue":276976000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":276976000,"period":"2025-12-31"},{"value":178957000,"period":"2024-12-31"},{"value":178957000,"period":"2024-12-31"},{"value":170276000,"period":"2023-12-31"},{"value":170276000,"period":"2023-12-31"}],"grossProfit":205617000,"grossProfitHistory":[{"period":"2025-12-31","value":205617000},{"period":"2024-12-31","value":106877000},{"period":"2023-12-31","value":94723000},{"period":"2022-12-31","value":127399000}],"rdSpend":93769000,"rdSpendHistory":[{"period":"2025-12-31","value":93769000},{"period":"2024-12-31","value":102953000},{"period":"2023-12-31","value":122117000},{"period":"2022-12-31","value":141756000}],"sgaSpend":167272000,"operatingIncome":-57123000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-57123000},{"period":"2024-12-31","value":-155344000},{"period":"2023-12-31","value":-201606000},{"period":"2022-12-31","value":-200186000}],"netIncome":-59499000,"netIncomeHistory":[{"period":"2025-12-31","value":-59499000},{"period":"2024-12-31","value":-159492000},{"period":"2023-12-31","value":-225250000},{"period":"2022-12-31","value":-200191000}],"eps":-0.39,"epsHistory":[{"period":"2025-12-31","value":-0.39},{"period":"2024-12-31","value":-1.08},{"period":"2023-12-31","value":-1.56},{"period":"2022-12-31","value":-1.4}],"cash":70495000,"cashHistory":[{"period":"2025-12-31","value":70495000},{"period":"2024-12-31","value":47920000},{"period":"2023-12-31","value":65064000},{"period":"2022-12-31","value":90030000}],"totalAssets":512736000,"totalLiabilities":287735000,"totalDebt":79148000,"equity":218793000,"operatingCashflow":-45986000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-45986000},{"period":"2024-12-31","value":-95212000},{"period":"2023-12-31","value":-156324000},{"period":"2022-12-31","value":-183945000}],"capex":-2959000,"capexHistory":[{"period":"2025-12-31","value":-2959000},{"period":"2024-12-31","value":-3664000},{"period":"2023-12-31","value":-10697000},{"period":"2022-12-31","value":-16349000}],"freeCashflow":-48945000,"dividendsPaid":null,"buybacks":null,"employees":624,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":44038000,"ebit":-10625000,"ebitda":-6430000,"period":"2025-12-31","revenue":71681000,"epsBasic":-0.09,"netIncome":-13579000,"rdExpense":21763000,"epsDiluted":-0.09,"grossProfit":53457000,"operatingIncome":-12773000},{"sga":41429000,"ebit":12516000,"ebitda":16921000,"period":"2025-09-30","revenue":93973000,"epsBasic":0.06,"netIncome":9546000,"rdExpense":23669000,"epsDiluted":0.06,"grossProfit":75816000,"operatingIncome":10290000},{"sga":41359000,"ebit":-22645000,"ebitda":-18143000,"period":"2025-06-30","revenue":58879000,"epsBasic":-0.17,"netIncome":-25614000,"rdExpense":24134000,"epsDiluted":-0.17,"grossProfit":40880000,"operatingIncome":-25036000},{"sga":40446000,"ebit":-26925000,"ebitda":-22194000,"period":"2025-03-31","revenue":52443000,"epsBasic":-0.2,"netIncome":-29852000,"rdExpense":24203000,"epsDiluted":-0.2,"grossProfit":35464000,"operatingIncome":-29604000},{"sga":39631000,"ebit":-30765000,"ebitda":-26317000,"period":"2024-12-31","revenue":47459000,"epsBasic":-0.23,"netIncome":-33692000,"rdExpense":23192000,"epsDiluted":-0.23,"grossProfit":29414000,"operatingIncome":-33837000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":13.15,"previousClose":13.13,"fiftyTwoWeekHigh":20.76,"fiftyTwoWeekLow":8.5,"fiftyTwoWeekRange":"8.5 - 20.76","fiftyDayAverage":14.02,"twoHundredDayAverage":15.03,"beta":2.16,"enterpriseValue":2099130880,"forwardPE":-50.6,"priceToBook":9.7,"priceToSales":7.12,"enterpriseToRevenue":7.11,"enterpriseToEbitda":-70.47,"pegRatio":0,"ebitda":-29786000,"ebitdaMargin":-10.1,"freeCashflow":16102625,"operatingCashflow":-27039000,"totalDebt":208180992,"debtToEquity":92.8,"currentRatio":3.35,"returnOnAssets":-5.7,"returnOnEquity":-24,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":20.14,"targetHighPrice":22,"targetLowPrice":18,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.8,"institutionHeldPercent":95.6,"sharesOutstanding":160044392,"floatShares":125373975,"sharesShort":8439712,"shortRatio":5.2,"shortPercentOfFloat":5.3,"epsTrailing":-0.32,"epsForward":-0.26,"revenuePerShare":1.93,"bookValue":1.35,"officers":[{"age":50,"name":"Mr. Chad M. Robins M.B.A.","title":"Co-Founder, CEO & Chairman"},{"age":53,"name":"Ms. Julie  Rubinstein","title":"President & COO"},{"age":52,"name":"Dr. Harlan S. Robins Ph.D.","title":"Co-Founder & Chief Scientific Officer"},{"age":41,"name":"Mr. Kyle  Piskel","title":"VP, CFO & Principal Accounting Officer"},{"age":44,"name":"Ms. Susan  Bobulsky","title":"Chief Commercial Officer of MRD"},{"age":null,"name":"Mr. Christopher  Carlson Ph.D.","title":"Founder"},{"age":null,"name":"Ms. Karina  Calzadilla","title":"Vice President of Investor Relations"},{"age":null,"name":"Ms. Clarice  McCauley","title":"Head of Legal, Corporate Secretary, VP & Chief Compliance Officer"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.adaptivebiotech.com","phone":"206 659 0067"}}